Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Financial support is being provided as a grant from the Government of India
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Subscribe To Our Newsletter & Stay Updated
